significantly increased activation of CREB protein in cells expressing TA4 CAM compared to TA4 (Figures 1a and b; P < 0.05). An alternative attempt for evaluating the activity of the CRE transduction pathway was performed by using a gene reporter system with a CRE promoter (Invitrogen LyticBlazer with HEK293-CREbla cells). The cells expressing TA4 CAM of either allele showed a significant increase in the response ratio (Figure 1c ; P < 0.01 respectively P < 0.05), whereas there was no significant difference between the two alleles of TA4.
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Our approach shows that CAM receptors can be used to analyze the effect of potential disease mutations on orphan receptor activity without knowledge of the endogenous ligand, where otherwise inferences can only be made on basis of the sequence differences revealed by linkage studies. These three different approaches confirm that TA4 R130D is a CAM GPCR in vivo and is likely to activate the CREB pathway in endogenous cells, comparably to TA1 and TA2. 2, 3 Furthermore, the assays did not show a significant difference of the CRE pathway activity between the two TA4 alleles G and A. The polymorphism leading to a conservative amino-acid exchange in the sixth transmembrane domain of TA4 does not alter the receptor activity in the assays described, and it does not promote constitutive activity as described for mutations in other diseases.
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Although these data do not provide evidence for an altered receptor activity of this TA4 polymorphism, an involvement in BPAD cannot be excluded based on our in vitro data. The polymorphism could influence other signal-transduction pathways of endogenous TA4 or influence ligand binding and thereby modulate the TA4 activity in humans. Several studies have demonstrated reductions in temporal lobe volume in people with bipolar disorder compared with controls. 1 Some studies have found that grey matter loss correlates negatively with age, 2 raising the possibility that deficits are associated with illness progression. This evidence is supported by a recent prospective imaging study, which found greater temporal and cerebellar grey matter reductions over time in people with bipolar disorder compared to controls, which was correlated with the number of intervening illness episodes. 3 The mechanism that leads to temporal grey matter reduction is, however, unclear. Post mortem evidence of gliosis and cell death is lacking for affective psychosis, 4 suggesting that deficits may be due to reduced neuropil or dendritic arborization. Brain derived neurotrophic factor (BDNF) is associated with multiple cell actions such as cytoskeletal remodelling and neurite outgrowth that could account for these grey matter reductions. 5 This possibility is further supported by an association between reduced hippocampal volume and BDNF genotype in healthy subjects. 6 A frequent, nonconservative single nucleotide polymorphism in the human BDNF gene (dbSNP number rs6265) produces a valine to methionine amino acid substitution at codon 66 (Val 66 Met). The met allele is associated with poorer episodic memory, abnormal hippocampal activation, and neurons transfected with met-BDNF-GFP showed lower depolarization-induced secretion. 7 Whether the BDNF Val 66 Met variant is associated with progressive temporal grey matter reductions and illness progression is not known.
This study sought to test the hypothesis that the individuals with the BDNF met variant would show greater temporal grey matter reductions and have more episodes of affective illness than those who carry at least one valine allele. To test this hypothesis, we used structural imaging data from 20 individuals with bipolar disorder scanned 4 years apart on a 1.5T GE LX scanner in Edinburgh. BDNF Val
66
Met genotype was determined using TaqMan 5 0 -exonuclease assay (AssayByDesign). Grey matter loss in Bipolar I Disorder patients with at least one met allele (N = 6) was contrasted with that in patients with no met alleles (N = 14) using SPM2, using tensor-based morphometry as described in our previous study. 3 Since our hypothesis was restricted to the temporal lobe, we applied a small volume correction for that region. The number of episodes of depression, mania/ hypomania and total number of affective episodes were also compared between the groups using a Mann-Whitney U-test.
No differences were found between BDNF met carriers and non-carriers in terms of age, sex or the number of affective illness episodes occurring over the intervening 4-year period. BDNF met carriers showed significantly greater temporal lobe reductions than non-carriers (peak Montréal Neurological Institute coordinates (À51, À36, À6): t = 6.02, voxel corrected P-value = 0.007: Figure 1 ). The cluster of grey matter reduction (thresholded at P = 0.005) extended also to the left lateral hippocampus. A greater proportion of hippocampus was occupied by the cluster at lower thresholds.
Here we have shown for the first time that the BDNF Val 66 Met polymorphism is associated with temporal lobe grey matter loss over 4 years in patients with Bipolar I Disorder. This effect may derive from the decreased activity of the BDNF met allele resulting in reduced trophic support in the temporal lobe. This effect could not be explained in terms of number of illness episodes. While this result clearly requires further replication in a larger sample, the BDNF met allele appears to have demonstrable effects on changes in temporal lobe structure in bipolar disorder that can be detected in a relatively small sample. Letters to the Editor
